Abiomed First Quarter Fiscal 2017 Earnings and Conference Call Notification
July 07 2016 - 8:00AM
Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, July 28,
2016, the Company will release financial results for the first
quarter of fiscal 2017. The Company will host a conference call to
discuss the results on Thursday, July 28, 2016, at 8:00 a.m. EDT.
Michael R. Minogue, Chairman, President and Chief Executive
Officer; Michael Tomsicek, Vice President and Chief Financial
Officer, will host the conference call.
To listen to the call live, please tune into the webcast via
http://investor.abiomed.com or dial (855) 212-2361; the
international number is (678) 809-1538. A replay of this
conference call will be available beginning at 11 a.m. EDT July 28,
2016 through 11:59 p.m. EDT on July 30, 2016. The replay phone
number is (855) 859-2056; the international number is (404)
537-3406. The replay access code is 44717460.
ABOUT ABIOMED Based in Danvers,
Massachusetts, Abiomed, Inc., is a leading provider of medical
devices that provide circulatory support. Our products are
designed to enable the heart to rest by improving blood flow and/or
performing the pumping of the heart. For additional information
please visit: www.abiomed.com
FORWARD-LOOKING STATEMENTS This
release contains forward-looking statements, including statements
regarding development of Abiomed's existing and new products, the
Company's progress toward commercial growth, and future
opportunities and expected regulatory approvals. The Company's
actual results may differ materially from those anticipated in
these forward-looking statements based upon a number of factors,
including uncertainties associated with development, testing and
related regulatory approvals, including the potential for future
losses, complex manufacturing, high quality requirements,
dependence on limited sources of supply, competition, technological
change, government regulation, litigation matters, future capital
needs and uncertainty of additional financing, and other risks and
challenges detailed in the Company's filings with the Securities
and Exchange Commission, including the most recently filed Annual
Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are
cautioned not to place undue reliance on any forward-looking
statements, which speak only as of the date of this release. The
Company undertakes no obligation to publicly release the results of
any revisions to these forward-looking statements that may be made
to reflect events or circumstances that occur after the date of
this release or to reflect the occurrence of unanticipated
events.
For further information please contact:
Ingrid Goldberg
Director, Investor Relations
978-646-1590
igoldberg@abiomed.com
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Apr 2023 to Apr 2024